<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400098</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 420915-CS5</org_study_id>
    <nct_id>NCT03400098</nct_id>
  </id_info>
  <brief_title>ATTR Expanded Access Program (EAP) by Ionis</brief_title>
  <official_title>Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this program is to provide expanded access to Inotersen for up to 100 Patients
      with Hereditary Transthyretin Amyloidosis (hTTR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Program is intended to provided expanded access to Inotersen for eligible patients with
      hATTR who have limited or no available treatment options.
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Amyloidosis, Hereditary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotersen</intervention_name>
    <description>Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age with a diagnosis of hATTR

          -  Symptoms consistent with polyneuropathy

          -  Meet Polyneuropathy Disability (PND) Stage I-III requirements

        Exclusion Criteria:

          -  Known Primary Amyloidosis, Leptomeningeal Amyloidosis or Monoclonal Gammopathy of
             Undetermined Significance or Multiple Myeloma

          -  Have inadequate cardiac function

          -  Have low platelet counts

          -  Have inadequate renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

